Literature DB >> 15339865

Woldemar Mobitz and His 1924 classification of second-degree atrioventricular block.

Mark E Silverman1, Charles B Upshaw, Helmut W Lange.   

Abstract

Woldemar Mobitz, an early 20th century German internist, analyzed arrhythmias by graphing the relationship of changing atrial rates and premature beats to AV conduction. Through an astute mathematical approach, he was able to classify second-degree atrioventricular block into 2 types, subsequently referred to as Mobitz type I (Wenckebach) and Mobitz type II (Hay). Type I AV block was most often due to digitalis and was reversible. There were no associated pathological findings. Type II AV block frequently progressed to complete AV block and was associated with seizures, death, and pathological findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339865     DOI: 10.1161/01.CIR.0000140669.35049.34

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

1.  Unusual origin of type 1 atrioventricular block with comments on Wenckebach's contribution.

Authors:  Anumeha Tandon; Leo Simpson; Manish D Assar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-01

2.  Simulation of Cardiac Arrhythmias Using a 2D Heterogeneous Whole Heart Model.

Authors:  Minimol Balakrishnan; V Srinivasa Chakravarthy; Soma Guhathakurta
Journal:  Front Physiol       Date:  2015-12-21       Impact factor: 4.566

3.  Mobitz type I and II atrioventricular blocks during fingolimod therapy.

Authors:  Francesco Saccà; Giorgia Puorro; Angela Marsili; Chiara Pane; Cinzia Valeria Russo; Roberta Lanzillo; Anna de Rosa; Antonio Cittadini; Giuseppe De Angelis; Vincenzo Brescia Morra
Journal:  Neurol Sci       Date:  2016-05-25       Impact factor: 3.307

4.  Trpm4 gene invalidation leads to cardiac hypertrophy and electrophysiological alterations.

Authors:  Marie Demion; Jérôme Thireau; Mélanie Gueffier; Amanda Finan; Ziad Khoueiry; Cécile Cassan; Nicolas Serafini; Franck Aimond; Mathieu Granier; Jean-Luc Pasquié; Pierre Launay; Sylvain Richard
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.